Clinical trials
Neoplasms trials in Portugal
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
92 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 1 |
| 2004 | 2 |
| 2005 | 2 |
| 2006 | 2 |
| 2007 | 3 |
| 2008 | 2 |
| 2011 | 2 |
| 2012 | 2 |
| 2013 | 4 |
| 2014 | 1 |
| 2015 | 5 |
| 2016 | 3 |
| 2017 | 4 |
| 2018 | 5 |
| 2019 | 13 |
| 2020 | 8 |
| 2021 | 4 |
| 2022 | 3 |
| 2023 | 6 |
| 2024 | 4 |
| 2025 | 7 |
| 2026 | 5 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 45 |
| Recruiting | 17 |
| Active, not recruiting | 16 |
| Unknown status | 6 |
| Not yet recruiting | 4 |
| Terminated | 4 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| AbbVie | 9 |
| Amgen | 6 |
| Hoffmann-La Roche | 6 |
| AstraZeneca | 5 |
| Astellas Pharma Global Development, Inc. | 4 |
| Sanofi | 4 |
| Fundación para la Investigación del Hospital Clínico de Valencia | 3 |
| MedImmune LLC | 3 |
| University of Coimbra | 3 |
| Bayer | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Neoplasms | 92 |
| Breast Neoplasms | 14 |
| Neoplasm Metastasis | 14 |
| Carcinoma, Non-Small-Cell Lung | 9 |
| Neoplasms by Site | 8 |
| Pancreatic Neoplasms | 7 |
| Colorectal Neoplasms | 6 |
| Lung Neoplasms | 6 |
| Lymphoma, Non-Hodgkin | 6 |
| Adenocarcinoma | 5 |
Trials
Showing 26 to 50 of 92. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.